Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease

Sugiyama, Seigo; Fukushima, Hisaaki; Kugiyama, Kiyotaka; Maruyoshi, Hidetomo; Kojima, Sunao; Funahashi, Tohru; Sakamoto, Tomohiro; Horibata, Yoko; Watanabe, Keisuke; Koga, Hidenobu; Sugamura, Koichi; Otsuka, Fumiyuki; Shimomura, Iichirou; Ogawa, Hisao

doi:10.1016/j.atherosclerosis.2006.08.023

Cited by 78 publications

(56 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result supports existing reports showing a beneficial effect of pravastatin on adiponectin concentration [9][10][11] . In addition, it was a novel finding in our study that this beneficial effect of pravastatin was increased in combination with TZD.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Pravastatin Potentiates Increases in Serum Adiponectin Concentration in Dyslipidemic Patients Receiving Thiazolidinedione: the DOLPHIN Study

Nezu

Tsunoda

Yoshimura

et al. 2010

JAT

View full text Add to dashboard Cite

Aim: A reduced risk of type 2 diabetes has been reported following treatment with pravastatin. Adiponectin is an adipocyte-derived protein that has an antidiabetic property. The objective of this study was to evaluate the effect of pravastatin on serum adiponectin concentration and other influencing factors. Methods: This study was a multicenter observational study: Dyslipidemia Open-labeled observational study by Lipid-lowering therapy with Pravastatin of the effect on High-molecular weight adiponectin in Nippon Yokohama (DOLPHIN). The protocol was registered in the UMIN Clinical Trial Registry as UMIN000000791. All patients received pravastatin 10 mg/day for 6 months and the change in concentration of total and high molecular weight adiponectin was assessed before and after follow-up. The difference in the change in total adiponectin concentration by patient characteristics was analyzed by an unpaired t-test. Influences of continuous variable factors on the change in total adiponectin concentration were estimated by simple linear regression analyses. Finally, in order to estimate the influences of factors that potentially affect the change in total adiponectin concentration induced by pravastatin, multiple linear regression analysis was conducted. Results: After 6 months, total adiponectin concentration was increased significantly by 23.2% from 11.7 6.4 to 13.7 8.6 g/mL (p 0.002). The use of thiazolidinedione as a concomitant medication was the only significant influencing factor ( 0.580, p 0.001). Conclusion: Pravastatin increased the serum adiponectin concentration in Japanese dyslipidemic patients without previous coronary artery disease. Interestingly, this effect was seen synergistically in combination with thiazolidinedione.

show abstract

Section: Discussionsupporting

confidence: 92%

“…Although the mechanism is not fully understood, several reports have shown that pravastatin increased plasma adiponectin levels [9][10][11] . It is likely that increased adiponectin enhanced insulin-induced glucose uptake and restrained the development of diabetes.…”

Section: Introductionmentioning

confidence: 99%

Pravastatin Potentiates Increases in Serum Adiponectin Concentration in Dyslipidemic Patients Receiving Thiazolidinedione: the DOLPHIN Study

Nezu

Tsunoda

Yoshimura

et al. 2010

JAT

View full text Add to dashboard Cite

show abstract

“…Pitavastatin and pravastatin elevate adiponectin expression in adipocytes 80) . Clinically, the adiponectin-elevating effects differ among statins [81][82][83][84] , and pitavastatin reportedly increases adiponectin levels in hyperlipidemic patients with diabetes mellitus. Suppression of reactive oxygen species (ROS) production, and activation of SREBP1c and PPAR have been proposed as possible mechanisms 85) .…”

Section: Other Factors Involved In Rct 1) Adiponectinmentioning

confidence: 98%

Molecular Mechanisms of HDL-Cholesterol Elevation by Statins and Its Effects on HDL Functions

Yamashita

Tsubakio-Yamamoto

Ohama

et al. 2010

JAT

View full text Add to dashboard Cite

“…4 Pravastatin (PRA), a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin), also prevents new onset of DM 5 and improves glucose tolerance in patients. [6][7][8] We and others have shown that PRA upregulates adiponectin messenger RNA expression in adipose tissue 8 and in cultured adipocytes, 9 and prevents the development of DM in animal models. [9][10][11] Clinical studies have also shown that PRA treatment increases plasma adiponectin in patients with hypercholesterolemia and is associated with improved glucose metabolism.…”

Section: Introductionmentioning

confidence: 97%

“…[9][10][11] Clinical studies have also shown that PRA treatment increases plasma adiponectin in patients with hypercholesterolemia and is associated with improved glucose metabolism. 8,9 As dyslipidemia often accompanies hypertension, such individuals are frequently treated with both reninangiotensin system inhibitors and statins. Several preclinical studies have shown that ARBs and statins additively or synergistically prevent cardiovascular remodeling.…”

Section: Introductionmentioning

confidence: 99%

Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model

et al. 2009

View full text Add to dashboard Cite

Hypertension and dyslipidemia frequently coexist in patients with progressive insulin resistance and thus constitute metabolic syndrome. We sought to determine the merits of combining an angiotensin II receptor blocker and a 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor in treating this pathological condition. Five-week-old Otsuka Long-Evans Tokushima Fatty rats, a model of metabolic syndrome, were untreated or treated with olmesartan 3 mg kg À1 per day, pravastatin 30 mg kg À1 per day or their combination for 25 weeks. Long-Evans Tokushima Otsuka rats served as normal controls. The antihypertensive effect of olmesartan and the lipid-lowering properties of pravastatin were both augmented by the combination. The oral glucose tolerance test revealed that only the combined treatment significantly reduced the area under the time-glucose curve, which was accompanied by augmented adiponectin messenger RNA expression in epididymal adipose tissue. Although the total cardiac endothelial nitric oxide synthetase (eNOS) content did not significantly differ among the groups, the combined treatment significantly increased the content of dihydrofolate reductase, a key eNOS coupler. Dihydroethidium staining of the aorta showed that the combination most significantly attenuated superoxide production. Moreover, Azan-Mallory staining revealed that the combination most significantly limited the perivascular fibrosis and wall thickening of intramyocardial coronary arteries. In conclusion, the combination of olmesartan and pravastatin augmented adiponectin expression in white adipose tissue and improved glucose tolerance in a rat model of metabolic syndrome, which was associated with more significant ameliorations of cardiovascular redox state and remodeling than those by treatments with either agent alone.

show abstract

Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease

Cited by 78 publications

References 28 publications

Pravastatin Potentiates Increases in Serum Adiponectin Concentration in Dyslipidemic Patients Receiving Thiazolidinedione: the DOLPHIN Study

Pravastatin Potentiates Increases in Serum Adiponectin Concentration in Dyslipidemic Patients Receiving Thiazolidinedione: the DOLPHIN Study

Molecular Mechanisms of HDL-Cholesterol Elevation by Statins and Its Effects on HDL Functions

Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model

Contact Info

Product

Resources

About